ReviewPediatric nephrology (Berlin, Germany)2014
Is rituximab effective in childhood nephrotic syndrome? Yes and no.
Review in Pediatric nephrology (Berlin, Germany), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Pediatric idiopathic steroid-sensitive nephrotic syndrome: diagnosis and therapy -short version of the updated German best practice guideline (S2e) - AWMF register no. 166-001, 6/2020.Pediatric nephrology (Berlin, Germany) · 2021Guideline
- Second and Third Generational Advances in Therapies of the Immune-Mediated Kidney Diseases in Children and Adolescents.Children (Basel, Switzerland) · 2022Review
- Rituximab treatment for difficult-to-treat nephrotic syndrome in children: a multicenter, retrospective studyTurkish journal of medical sciences · 2021Article
- Difficult-to-treat idiopathic nephrotic syndrome: established drugs, open questions and future options.Pediatric nephrology (Berlin, Germany) · 2018Review
- Immunology of idiopathic nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2018Review
- Focal segmental glomerulosclerosis in children complicated by posterior reversible encephalopathy syndrome.The Journal of international medical research · 2018Article
- Steroid-resistant nephrotic syndrome: past and current perspectives.Pediatric health, medicine and therapeutics · 2017Review
- Optimal management of primary focal segmental glomerulosclerosis in adults.International journal of nephrology and renovascular disease · 2017Review
- B Cell Reconstitution after Rituximab Treatment in Idiopathic Nephrotic Syndrome.Journal of the American Society of Nephrology : JASN · 2016Article
- Cyclophosphamide and rituximab in frequently relapsing/steroid-dependent nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2016Article
- Recent Advances in Treatments of Primary Focal Segmental Glomerulosclerosis in Children.BioMed research international · 2016Review
- Immunologic Changes Implicated in the Pathogenesis of Focal Segmental Glomerulosclerosis.BioMed research international · 2016Review
- Pharmacokinetics of rituximab in a pediatric patient with therapy-resistant nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2015Article
- Is there B cell involvement in a rat model of spontaneous idiopathic nephrotic syndrome treated with LF15-0195?Journal of nephrology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The idiopathic nephrotic syndrome (i.e. MCNS and FSGS) in children has been regarded as a disorder of T-cell function. Recent studies, however, also describe abnormalities of B-cell function. This supports the use of B-cell modulating treatment for idiopathic nephrotic syndrome (INS), especially rituximab, which has been used in other glomerular disorders as well. Many studies indicate that rituximab is effective in steroid-sensitive and -dependent nephrotic syndrome, by either inducing long-term remission or reducing relapses. In most series, children with primary (and recurrent) focal segmental glomerulosclerosis (FSGS) do not respond as well. The exact mechanisms of action of rituximab (as well as those of the other treatment options) in INS are as yet unclear. In addition to hosting mechanisms a direct stabilizing effect on the podocyte may also be of relevance, especially in FSGS. Although results are encouraging especially in steroid-sensitive patients, further studies on the clinical use of rituximab and the short- and long-term immunological effects and side-effects are necessary.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.